TransCode Therapeutics amends Series C Preferred beneficial ownership limit from 4.99% to 9.99%

Transcode Therapeutics, Inc.

Filed Amended and Restated Certificate of Designation for Series C Non-Voting Convertible Preferred Stock.
Beneficial ownership limitation increased to 9.99% from 4.99%.
Amendment approved by majority of Series C holders and Board of Directors.
No new securities issued; only scrivener's errors corrected.
Effective July 16, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.